Clinical Trial Update: A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3) [Phase 3]

View source ↗

Summary

This clinical trial update indicates that a Phase 3 long-term safety study (BALSAM-3) of KarXT in adults with Bipolar I disorder with mania is currently recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder Type

Drugs mentioned

• KarXT (xanomeline-trospium)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Bipolar Disorder Type I With Mania | Phase 3 | Status: RECRUITING